Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Web site

<< Previous

Bullboard Posts

Next >>

Comment by Golddetectoron May 09, 2022 4:51pm

127 Views

Post# 34668505

RE:RE:RE:RE:RE:Web site

You go by date. However, Reduvo application exceeded the time followed in the guidelines. I think it is 180 days for application use 3rd party data. Some other types need 300days we passed both. However, It all depends on the time used back and forth for clarifications. Tbp did not provide more than "working on a final statement" in their recent update on April 14. I hope it is coming soon. The biggest concern for tbp was the financing as they had 3.7M in their account end of Feb and there was a risk that they won't be able to secure funds. That is why last week news was very good so we do not worry about it

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?